Cell cycle control as a promising target in melanoma
- 1 March 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 27 (2) , 141-150
Abstract
This review highlights recent clinical developments in the therapeutic targeting of cell cycle control in melanoma with cyclin-dependent kinase inhibitors, checkpoint kinases, MDM2, MDM4 and p53 inhibitors. The high prevalence of activating genetic aberrations along the p16 INK4A:cyclinD-CDK4/6:RB pathway in melanoma and increasing evidence that alterations in this pathway are linked to melanomagenesis, make targeting the p16 INK4A:cyclinD-CDK4/6:RB pathway in melanoma logical and highly attractive. The presence of elevated CDK4 activity appears to correlate with greater CDK4/6 inhibitor therapeutic activity, whereas the loss of RB1 has been linked to CDK inhibitor resistance. Other novel compounds targeting cell cycle control via reactivating wild-type p53 and checkpoint kinases are also currently under investigation in melanoma. Cell cycle control is a promising target in the management of melanoma with early data reporting therapeutic benefit with cyclin-dependent kinase inhibitors, MDM2, and p53 reactivation compounds. Many of these drugs have entered phase I and II clinical trial development. Preliminary data from these studies are discussed in this review along with future treatment strategies for maximizing treatment outcomes in advanced melanoma. http://links.lww.com/COON/A12.Keywords
This publication has 39 references indexed in Scilit:
- Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarkerJournal of Clinical Pathology, 2014
- Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell linesPigment Cell & Melanoma Research, 2014
- Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future ProspectsJNCI: Journal of the National Cancer Institute, 2014
- Frequency of somatic BRAF mutations in melanocytic lesions from patients in a CDK4 melanoma familyPigment Cell & Melanoma Research, 2013
- Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)Clinical Cancer Research, 2013
- p16INK4a deficiency promotes DNA hyper‐replication and genetic instability in melanocytesPigment Cell & Melanoma Research, 2012
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanomaNature Medicine, 2012
- A Landscape of Driver Mutations in MelanomaCell, 2012
- High Frequency of p16 Promoter Methylation in NRAS-Mutated Cutaneous MelanomaJournal of Investigative Dermatology, 2010
- The landscape of somatic copy-number alteration across human cancersNature, 2010